← All stocks

Pyxis Oncology, Inc.

PYXS Scheduled selling only

CIK 0001782223 #3722 in the set updated 20 Sep 2026

Bought (12 mo)

$0.00

out of their own pocket, the only kind of buying there is

Sold (12 mo)

$107.10K

$0.00 on a plan · $107.10K straight out of an exercise

Sold at will

$0.00

0 of 1 sales

Net

−$107.10K

$0.00 against sales at will

By person

4 insiders · 1 transaction

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Dupont Jakob

Director

—

$107.10K (1) scheduled

−$107.10K

38,741

0.0464%

$118.55K

0.0%

Connealy Pamela Ann

CFO & COO

—

1,199,143

1.44%

$3.67M

+8.0%

Wadhane Jitendra

Prin Fin & Acct Officer

—

512,882

0.6149%

$1.57M

+27.1%

HUMPHREY RACHEL

Director

—

81,309

0.0975%

$248.81K

−16.0%

Individual transactions

Nothing of that kind in this period.

What was left out

Form 4 filings counted 14

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 0

Sales on a Rule 10b5-1 plan 0

Sales straight out of an exercise 1

Sales at will 0

Transactions with no price 0

Shares from compensation/vesting 144,461

History held since 12 Oct 2021